- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy
Panelists discuss how promising ongoing and upcoming clinical trials may reshape sequencing strategies in ALK+ non–small cell lung cancer (NSCLC).
EP: 1.The Evolution of ALK+ NSCLC Care
EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3
EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC
EP: 5.Key Differences Among ALK Inhibitors
EP: 6.Navigating ALK Inhibitor Toxicities
EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs
EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors
EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization
EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC
EP: 11.Education and Support After Progression ALK Inhibitors
EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy
Future Directions
- Key Discussion Points:
- Dr Lovly highlighted promising clinical trials that may reshape ALK+ NSCLC treatment sequencing strategies
Notable Expert Insights
- Dr Dietrich provided critical analysis of the CROWN trial data and the implications of matching-adjusted indirect comparisons between different ALK inhibitors for clinical decision-making
- Dr Lovly offered specialized perspective on resistance patterns and mutation-guided therapy selection, particularly incorporating emerging data on investigational agents like NVL-655
- Elizabeth Castronovo contributed valuable real-world experience comparing clinical trial outcomes with observed patient responses and toxicity management approaches
- Mary Grizzard emphasized patient-centered care considerations, highlighting education strategies and practical challenges faced during treatment transitions
The panelists collectively addressed the evolving treatment landscape for ALK+ NSCLC, emphasizing evidence-based approaches to optimize patient outcomes through appropriate therapy selection, sequencing strategies, and adverse event management.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
